Introduction {#s1}
============

Diabetes mellitus (DM) is a metabolic disorder that is characterized by an abnormal long-term increase in plasma glucose levels. Diabetes is mainly classified into four types, i.e., type I diabetes (T1DM), type II diabetes (T2DM), gestational diabetes, and specific types of diabetes due to other causes ([@B18]). Many factors, such as insulin deficiency or resistance as well as altered carbohydrate, protein, and fat metabolisms, are usually the reasons for high blood glucose levels leading to DM. Chronic hyperglycemia related to diabetes is often associated with many other complications, such as cardiovascular, dermatological, neurological, renal, retinal, and nerve diseases. Diabetes is one of the most common chronic disease, and it has shown an increasing rate of occurrence over the past decade ([@B36]). According to the World Health Organization (WHO), the total number of people with diabetes worldwide substantially increased from 108 million in 1980 to 422 million in 2014 ([@B248]). Along with diabetes, the incidence of other metabolic diseases, such as hyperlipidemia, is also increasing rapidly ([@B132]).

Metabolic syndrome (MS) is associated with a group of disease conditions that occur together, and it is composed of central adiposity, hyperglycemia, hypertriglyceridemia, low high-density lipoproteins (HDL)-cholesterol, and hypertension. This disease cluster of diabetes and cardiovascular diseases is also known as "The Deadly Quartet", "Syndrome X", and "The Insulin Resistance Syndrome" ([@B15]). Various treatment options are available to mitigate MS, including the diabetic condition and related disorders ([@B65]). As MS is manifested by the cluster of diseases, use of a single drug candidate might not be able to provide necessary therapeutic effects. Plant extracts and isolated compounds can be possible options as adjuvants in such cases. Traditionally, various medicinal plants and their products (extracts and isolated compounds) have been used in the treatment of diabetes and hypertension ([@B182]; [@B227]; [@B202]; [@B80]). Various research showed the protective/curative effect of plant extracts as a whole and/or an individual bioactive compound against diabetes and other metabolic diseases ([@B228]; [@B239]).

Plants belonging to the genus *Berberis* (Family: Berberidaceae) are widely distributed worldwide with nearly 550 species. A decoction prepared from the roots of *Berberis* plants is one of the common traditional recipes for the treatment of diabetes ([@B180]). Various studies have reported the traditional uses *Berberis* plants for the treatment of metabolic diseases (e.g., diabetes and hyperlipidemia) in many countries, including India, Pakistan, China, and Iran ([@B99]; [@B236]; [@B193]; [@B196]). Various bioactive compounds, such as alkaloids, polyphenols, flavonoids, anthocyanins, etc., have been found in *Berberis* species along with various vitamins and mineral components ([@B19]; [@B223]; [@B30]; [@B31]). Berberine (BBR), a quaternary ammonium salt belonging to a group of benzylisoquinoline alkaloids, is the most active compound reported from *Berberis* species, and it is considered to be highly effective against diabetes and other metabolic diseases ([@B76]; [@B152]; [@B245]). BBR is also distributed in various plant species of other genera such as *Coptis*, *Hydrastis*, *Mahonia*, *Tinospora*, *Xanthorhiza*, and many others ([@B180]). In the genus *Berberis*, the distribution of BBR and other alkaloids is mostly in its root part, followed by the stem bark and the stem itself ([@B19]). In addition, its presence in trace amounts has been reported from leaves and berries. Various studies have been conducted to evaluate the effectiveness of *Berberis* extract or bioactive alkaloidal compounds against diabetes and other MS with promising results ([@B97]; [@B170]; [@B111]; [@B175]). Moreover, various clinical trials were also conducted on testing their effectiveness against diabetes and other metabolic diseases and showed variable effects ([@B265]; [@B183]).

Considering the *Berberis* species and their active alkaloidal components, the present review specifically focuses on their effectiveness against diabetes and other metabolic diseases. This review discusses various traditional uses of *Berberis* against metabolic diseases, along with its cell- and animal-model studies. The pharmacological effects of *Berberis* extracts and alkaloids against diabetes and other metabolic diseases are also discussed along with the molecular mechanism of action. Furthermore, based on the present studies of *Berberis* species against diabetes and metabolic diseases, research gaps were highlighted, and future recommendations were made.

Methodology {#s2}
===========

The scattered scientific information on *Berberis* species and isolated compounds used to counteract metabolic diseases was collected and documented. The synonyms of the various species were crosschecked with the plant name database The Plant List ([www.theplantlist.org](www.theplantlist.org), Retrieved on November 22, 2019). Afterwards, the available articles on respective species were retrieved using popular search engines and various databases, such as SciFinder, ScienceDirect, PubMed, Scopus, Mendeley, JOAP, Microsoft academic, and Google Scholar. The keywords used were *Berberis*, berberine, diabetes, metabolic diseases, metabolic syndrome, ethnopharmacology, ethnobotany, chemical constituents, alkaloids, *in vitro*, *in vivo*, clinical study, and clinical trials. The data were congregated through the Boolean information retrieval method by using a plant name along with an "AND" operator followed by diabetes and metabolic syndrome. No prerequisite limitations on publications, i.e., language, year, and publication type (original contribution, review article, or key editorial note), were taken into consideration.

Taxonomy and Ecology of Genus *Berberis* {#s3}
========================================

According to The Plant List database ([www.theplantlist.org](www.theplantlist.org), retrieved on September 20, 2019), the family Berberidaceae consists of a total of 19 genera. The members of the genus *Berberis* are reported to be difficult to identify taxonomically due to their extreme morphological variation in relation to the environmental factors and natural hybridization ([@B11]; [@B198]). Various overlapping morphological characters, such as flowers, leaves, stems, and berries---which also depend upon the season---and plant age also make it difficult to identify during field tasks ([@B197]; [@B198]; [@B233]). *Berberis* species are widely cultivated around the world due to their high medicinal and ornamental value. Most members of the genus *Berberis* are reported to be tolerant to shade, resistant to drought, and widely distributed in open and wooded habitats and wetlands. These plants are also studied as indicators of habitat degradation in the temperate region due traditionally to their thorny stem and unpalatable shoots ([@B41]). Representative photographs of some *Berberis* species from the Indian Himalayan Region (IHR) are shown in [**Figure 1**](#f1){ref-type="fig"}, and their major plant parts used to extract berberine and other bioactive alkaloids are shown in [**Figure 2**](#f2){ref-type="fig"}.

![Some *Berberis* species of Indian Himalayan Region (IHR). **(A)** *B. aristata* DC., **(B)** *B. asiatica* Roxb. ex DC., **(C)** *B. jaeschkeana* C.K.Schneid., **(D)** *B. lycium* Royle, **(E)** *B. pseudumbellata* R. Parker, **(F)** *B. thomsoniana* Schneider.](fphar-11-00041-g001){#f1}

![Various plant parts of **(A)** *Berberis asiatica* collected from Indian Himalayan Region (IHR), includes, **(B)** roots, **(C)** stems and **(D)** stem barks. These parts are the major sources to extract Berberine (yellow color) from *Berberis* species.](fphar-11-00041-g002){#f2}

Ethnopharmacology of *Berberis* spp. Against Diabetes and Other Metabolic Diseases {#s4}
==================================================================================

A literature review revealed that the ethnopharmacological uses of *Berberis* species have been documented from different parts of the world for the treatment of diabetes, hypertension, and obesity, and some of them also revealed the formulation methods. A majority of *Berberis* species were found to be used in the Himalayan region of India and Pakistan.

*B. lycium* Royle has been used traditionally for the treatment of diabetes mellitus and other diseases, particularly by the local inhabitants of the Himalayan region ([@B99]). Apart from diabetes, *B. lycium* is also used to treat bone fractures, diarrhoea, fever, intestinal colic, internal wounds, jaundice, menorrhagia, ophthalmic disorders, piles, rheumatism, sun blindness, and throat pain ([@B113]; [@B3]). Fruits and leaves of *B. lycium* are also reported to be used for the treatment of diabetes mellitus in south-west of Iran ([@B193]) and Pakistan ([@B263]). The water extract obtained by soaking the root bark in water is used for the treatment of diabetes ([@B9]). The whole plant is used to treat diabetes in Chamba district of Himachal Pradesh, West Himalaya, India ([@B196]). The Bhotiya tribal community of the Central Himalayan region of India used *B. lycium* roots with water for the treatment of diabetes ([@B188]).

The stem of *B. aristata* DC. is widely used in Indian traditional medicine for the treatment of diabetes ([@B237]), which is also reported in Ayurvedic Pharmacopoeia. The decoction (5--10 mL) of roots or stems of this species prepared with water was taken twice a day for 1--2 weeks to treat diabetes in Uttarakhand region ([@B149]). It is also used by Uttarakhand people for the treatment of hypertension ([@B219]). The root, stem, and fruit also have been used to treat obesity ([@B46]). *B. asiatica* is also used for the treatment of diabetes by the tribal communities of Chhota Bhangal, Western Himalaya, India. The decoction prepared from the roots is concentrated and dried in shade and then used with the sap of bitter guard for the treatment of diabetes ([@B236]).

In Iranian traditional medicine, *B. vulgaris* L. is extensively used to treat diabetes and hypertension ([@B194]). Local people use a decoction from the fruits and roots of *B. vulgaris* to treat hypertension ([@B26]). The fruits are most frequently used in traditional and modern medicine ([@B193]). Dried roots of *B. crateagina* DC. were recorded to be used as anti-diabetic agents locally in Turkey, and the decoction or infusion prepared from dried roots was taken orally one to two times a day for the treatment of diabetes ([@B78]). The anti-diabetic activity has also been reported for *B. brevissima* Jafri and *B. parkeriana* C.K.Schneid. ([@B16]). [@B27] reported that the inhabitant of Urmia, Iran, use boiled and steamed *B. integerrima* Bunge extract for the treatment of diabetes.

Alkaloids From *Berberis* Species: Potential Compounds Against Metabolic Diseases {#s5}
=================================================================================

A large number of studies have been conducted on the isolation and quantification of bioactive compounds from *Berberis* species. The phytochemical investigations of the genus *Berberis* have shown the presence of more than 105 compounds with varying structural confirmations. Most of the studies on *Berberis* species are focused on phytochemical screening; for the presence and estimation of different secondary metabolites, such as alkaloids, flavonoids, steroids, sugars, triterpenoids, tannins, and other preliminary assays such as total ash content, acid soluble ash content, and moisture content ([@B30]; [@B31]; [@B21]; [@B222]; [@B209]). However, the isolation and characterization of alkaloids from genus *Berberis* is well documented. Alkaloids are one of the major bioactive chemical constituents of the *Berberis* species, and they are responsible for various pharmacological activities of either whole extract or isolated individual compounds. Berberine (BBR) is one of the most commonly reported alkaloids from various *Berberis* species along with palmatine, magnoflorine, and jatrorrhizine, etc. ([**Figure 3**](#f3){ref-type="fig"}) ([@B33]; [@B86]). Simple isoquinolone alkaloids are mainly reported from these species; however, studies have also reported their dimmers or dimeric benzylisoquinoline alkaloids ([@B154]). The detailed list of different alkaloids isolated from various *Berberis* species are given in [**Table 1**](#T1){ref-type="table"}. Among other compounds, BBR and its various natural and synthetic derivatives have also been evaluated and found effective in prevention and treatment of MS ([@B183]; [@B156]; [@B270]).

![Structures of some of the main bioactive alkaloids from *Berberis* species.](fphar-11-00041-g003){#f3}

###### 

List of alkaloids isolated from various *Berberis* species.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Plant source                                      Plant parts                                                                                                                        Alkaloids                                                                                                                                                                                                                                             References
  ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------
  *B. acanthifolium* Mart. ex Schult. & Schult.f.   Stem bark                                                                                                                          Berberine, tetrahydropalmatine                                                                                                                                                                                                                        ([@B232])

  *B. aetnensis* C. Presl.                          Root                                                                                                                               Berberine                                                                                                                                                                                                                                             ([@B13])

  *B. amurensis* Rupr.                              Stem                                                                                                                               Berberine, palmatine, berberine                                                                                                                                                                                                                       ([@B249])

  *B. amurensis* Rupr.                              Young shoot                                                                                                                        Berberubine, oxyacanthine, pseudopalmatine, amurenine                                                                                                                                                                                                 ([@B262])

  *B. aristata* DC.                                 Stem bark                                                                                                                          Berberine phenoxide, ketoberberine benzoate A, ketoberberine benzoate B                                                                                                                                                                               ([@B6])

                                                    Root and stem bark                                                                                                                 Berberine, palmatine, berberrubine, jatrorrhizine, ketoberberine, dihydropalmatine,\                                                                                                                                                                  ([@B29])
                                                                                                                                                                                       berbamine, pakistanamine                                                                                                                                                                                                                              

  *B. asiatica* Roxb. ex DC.                        Root                                                                                                                               Berberine, oxyacanthine, berbamine, palmitine, jatrorrhizine, oxyberberine, tetrahydropalmatine, columbamine                                                                                                                                          ([@B32])

  *B. baluchistanica* Ahrendt                       Root                                                                                                                               Pakistanine, pakistanamine, baluchistanamine, gandharamine                                                                                                                                                                                            ([@B210]; [@B211]; [@B173]; [@B2])

  *B. buxifolia* Lam.                               --                                                                                                                                 Chillanamine, (-)-osornine, (-)-curacutine, (-)-talcamine                                                                                                                                                                                             ([@B154])

  *B. calliobotrys* Bien. ex Koehne                 Root                                                                                                                               Khyberine, pakistanamine, 1-O-methylpakistanine, pakistanine, chitraline, kalashine                                                                                                                                                                   ([@B85])

  *B. chitria* Buch.-Ham. ex Lindl.                 --                                                                                                                                 Berberine, palmatine, jatrorrhizine, oxyacanthine, *O*-methylcorydine-*N*-oxide                                                                                                                                                                       ([@B110])

  Root bark                                         Palmatine,                                                                                                                         ([@B53])                                                                                                                                                                                                                                              

  *B. coletioides* Lechl.                           \-                                                                                                                                 Pronuciferine *N*-oxide, pronuciferine                                                                                                                                                                                                                ([@B82])

  *B. concinna* Hook.f.                             Stem bark                                                                                                                          Berberine, tetrahydropalmatine                                                                                                                                                                                                                        ([@B232])

  *B. crataegina* DC.                               Stem and root                                                                                                                      Berberine, palmitine                                                                                                                                                                                                                                  ([@B187])

  Seed                                              Berbaine, oxyacanthine                                                                                                                                                                                                                                                                                                                                                                   

  *B. darwinii* Hook.                               --                                                                                                                                 magallanesine                                                                                                                                                                                                                                         ([@B238])

  *B. densiflora* Boiss. & Buhse                    Leaf                                                                                                                               Berberine, β-allocryptopine, densinine, densiberine, glaucine, oxyacanthine, thalicmidine, isocorydine, *O*-methylcorypalline                                                                                                                         ([@B140])

  *B. diaphana* Maxim.                              Bark                                                                                                                               Berberine, palmatine, magnoflorine, jatrorrhizine                                                                                                                                                                                                     ([@B86])

  *B. dictyophylla* Franch.                         Bark                                                                                                                               Berberine, palmatine, magnoflorine, jatrorrhizine                                                                                                                                                                                                     ([@B86])

  *B. glaucocarpa* Stapf                            Root                                                                                                                               Oxyacanthine, tetrandrine                                                                                                                                                                                                                             ([@B14])

  *B. heterobotrys* E.L.Wolf                        --                                                                                                                                 Berberine, palmatine, yatrorizine, oxyacanthine, berbamine, reticuline, obaberine, isocorydine, talikmidine, berberal.                                                                                                                                ([@B124])

  *B. heteropoda* Schrenk                           Young shoot and leaf                                                                                                               *N*-Methyldihydroberberine, 8-oxoberberrubine, berbamunine, aromoline, glaucine, talikmidine, isocorydine, reticuline, Pseudopalmatine, laudanosine, berpodine, isotetrandrine                                                                        ([@B122]; [@B123]; [@B261])

  *B. hispanica* Boiss. & Reut.                     Root bark                                                                                                                          Berberine tannate                                                                                                                                                                                                                                     ([@B22])

  *B. ilicifolia* L.f.                              --                                                                                                                                 Ilicifoline                                                                                                                                                                                                                                           ([@B81])

  *B. iliensis* Popov                               Young shoot                                                                                                                        (+)-β*-N*-Methylcorypalmine, berberrubine, berberine, magnoflorine                                                                                                                                                                                    ([@B120])

  *B. integerrima* Bunge                            --                                                                                                                                 Berberine, berbamunine, oxyacanthine, magnoflorin, intebrine, intebrinine, intebrimine                                                                                                                                                                ([@B121]; [@B129]; [@B130])

  *B. jaeschkeana* C.K. Schneid                     Root and bark                                                                                                                      Berberine                                                                                                                                                                                                                                             ([@B21])

  *B. jaeschkeana* Schneid var. *jaeschkeana*       --                                                                                                                                 Berberine, palmatine, jatrorrhizine, chondrofoline, berberidione                                                                                                                                                                                      ([@B13])

  *B. julianae* C.K. Schneid.                       Aerial part                                                                                                                        Berberine, magnoflorine, glaucine, tetrahydrojatrorrhizine                                                                                                                                                                                            ([@B35])

  *B. kansuensis* Schneid.                          Bark                                                                                                                               Berberine, palmatine, magnoflorine, jatrorrhizine                                                                                                                                                                                                     ([@B86])

  *B. laurina* Thunb.                               Leaf                                                                                                                               Berberine, (-)-tetrahydropalmatine, protopine                                                                                                                                                                                                         ([@B83])

                                                    Trunk bark and root                                                                                                                Berberine, obaberine (*O*-methyloxyacanthine), *O*-methylisothalicaberine, lauberine                                                                                                                                                                  ([@B83])

  *B. libanotica* Ehrenb.                           Root, fruit                                                                                                                        Oxycanthine, berbamine, jatrorrhizine, palmatine, berberine                                                                                                                                                                                           ([@B13]; [@B105])

  *B. lycium* Royle                                 Fruit                                                                                                                              Berberine, magnoflorine                                                                                                                                                                                                                               ([@B214])

  --                                                Berberine, berbericine                                                                                                             ([@B207])                                                                                                                                                                                                                                             

  *B. nummularia* Bunge                             Leaf                                                                                                                               Bernumine bernumidine and bernumicine, nummularine                                                                                                                                                                                                    ([@B126]; [@B84])

  *B. oblonga* Scheid                               Leaf                                                                                                                               Glaucine, hydroxyacanthin, berbamine, berberin, isocoridin                                                                                                                                                                                            ([@B141])

  --                                                Berberine, berbamunine, oxyacanthine, magnoflorine, palmitine, oblongamine                                                         ([@B121])                                                                                                                                                                                                                                             

  Root                                              Berberine iodide, magnoflorine iodide, columbamine iodide, oxyacanthine, berbamine, 2\'-*N*-methylisotetrandrine iodide            ([@B119])                                                                                                                                                                                                                                             

  Leaves and shoots                                 Thalicmidine and in the shoots, berberin. Other alkaloids isolated included glaucine, hydroxyacanthine, berbamine, isocoridine     ([@B141])                                                                                                                                                                                                                                             

  *B. pachycantha* Koehne                           Whole plant                                                                                                                        Pachycanthine                                                                                                                                                                                                                                         ([@B10])

  *B. petiolaris* Wall. ex G. Don                   Fruits, leaf, root and stem                                                                                                        Berberine, palmatine, magnoflorine, jatrorrhizine, tetrahydropalmatine, tetrahydroberberine, thalifendine/berberrubine, demethyleneberberine, reticuline, 8-oxoberberine, *N*-methyltetrahydroberberine,                                              ([@B218])

  Root                                              Berbamine, berberine chloride, palimitine                                                                                          ([@B172])                                                                                                                                                                                                                                             

  *B. sibirica* Pall.                               Aerial part                                                                                                                        (-)-Tetrahydropseudocoptisine, pseudoprotopine, (+)-chelidonine, (+)-glaziovine, berberine, palmatine, columbamine, berberubine, oxyacanthine, berbamine, 8-oxoberberine, 8-oxoberberubine, pakistanine, pronuciferine, *N*-acetylhomoveratrylamine   ([@B127]; [@B112])

  *B. tabiensis* L.A. Camargo                       Stem                                                                                                                               Tabienine                                                                                                                                                                                                                                             ([@B192])

  *B. thunbergii* DC                                Stem                                                                                                                               Berberine, berbamine, glaucine, isocorydine, oxycanthine, palmatine, thalicmidine                                                                                                                                                                     ([@B138])

  Leaf                                              Thalicmidine, oxycanthine, isocorydine, heliamine, berberine                                                                       ([@B138])                                                                                                                                                                                                                                             

  Fruit                                             Oxyxanthine, isotetrandrine, thalicmidine                                                                                          ([@B138])                                                                                                                                                                                                                                             

  --                                                Berberine, columbamine                                                                                                             ([@B181])                                                                                                                                                                                                                                             

  --                                                Oxyacanthine, palmatine, thalicmidine, isotetrandrine, berberine, berbamine, glaucine, isocorydine,heliamine                       ([@B139])                                                                                                                                                                                                                                             

  *B. turcomanica*\                                 Young shoot                                                                                                                        Turconidine                                                                                                                                                                                                                                           ([@B128])
  Kar. ex Ledeb.                                                                                                                                                                                                                                                                                                                                                                                                                             

  --                                                Turcberine                                                                                                                         ([@B125])                                                                                                                                                                                                                                             

  Young shoot                                       Berberine, isocorydine, glaucine, thalicmidine, aromoline, oxyacanthine, turcomanine, berberine, papaverine, cyclotriveratrilene   ([@B137]; [@B134])                                                                                                                                                                                                                                    

  Leaf                                              Turcomanidine, Turcamine,                                                                                                          ([@B135]; [@B136])                                                                                                                                                                                                                                    

  *B. vernae* Schneid.                              Bark                                                                                                                               Berberine, palmatine, magnoflorine, jatrorrhizine                                                                                                                                                                                                     ([@B86])

  *B. virgetorum* C.K. Schneid.                     Whole plant                                                                                                                        (-)-Berbervirine, berberine, jatrorrhizine, noroxyhydrastinine                                                                                                                                                                                        ([@B161])

  *B. vulgaris* L.                                  Root bark                                                                                                                          Berberine, palmatibne, bersavine, muraricine, berbostrejdine, berbamine, aromoline, obamegine, 8-oxoberberine, berbidine, bargustanine, Berberine, oxyacanthine, talikmidine, yatrorizine, berbamine, berbamunine, isocorydine                        ([@B131]; [@B133]; [@B104]; [@B106])

  *B. vulgaris* subsp. *australis* (Boiss.)         Root bark                                                                                                                          Berbamine, sotetrandrine, oxyacanthine, obaberine, aromoline, obamegine, thaligrisine, thalifoline, 8-oxyberberine, chilenine, (-)-tejedine                                                                                                           ([@B224])
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The effect of different habitat conditions (altitudinal variations and edaphic factors) of *Berberis* species has been investigated. [@B45] investigated eight *Berberis* species from different altitudinal range for determining the BBR concentration in different parts. Among these, *B. asiatica* was found to contain higher content of BBR than other species. Lower altitudinal range was found to contain higher BBR content within a species as compared to high altitude habitat. Among plant parts, roots contained a higher concentration of BBR ([@B45]). Similarly, variations in the BBR content of five *Berberis* species (i.e., *B. aristata, B. asiatica, B. jaeschkeana, B. lycium*, and *B. pseudumbellata*) depending upon the habitat have also studied. The presence of higher BBR content was recorded from rocky habitats in *B. jaeschkeana* ([@B21]). Both altitude and edaphic conditions were found to be responsible for the variation in BBR content in root and stem bark. Lower altitude populations showed significantly higher BBR content and positively correlated with moisture and potassium availability in soil species. Among these, *B. asiatica* contain significantly higher BBR content as compared to other species ([@B19]) Seasonal variations in the BBR content revealed higher percentage in summer and lower in rainy season ([@B21]). Low moisture and high soil potassium level is reported to be well correlated with high BBR content ([@B20]).

*In Vitro* Activities Against Diabetes and Other Metabolic Diseases {#s6}
===================================================================

It has been suggested that physical exercise and a proper diet can act as controllers of the cause of T2DM and metabolic diseases. Currently available pharmacological interventions can control many aspects of diabetes and metabolic diseases, like microvascular and macrovascular complications, hypertension, dyslipidemia, and obesity. However, there is also a need for novel therapeutic agents that work alone or in combination with currently available drugs. Within the pharmacological options, phytochemicals have a great potential to act against T2DM, MS, and associated complications ([@B64]). Extracts of *Berberis* species and their components, especially alkaloids, have been documented for their potential activity against T2DM and MS in various *in vitro* studies ([**Table 2**](#T2){ref-type="table"}) ([@B190])

###### 

*In vitro* activity of extracts and/or isolated compounds from *Berberis* species against diabetes and metabolic diseases.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Extracts from *Berberis* spp./isolated compounds              Model                                                       Outcomes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **References**
  ------------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Berberine (BBR)                                               Mouse 3T3-L1 cells                                          Downregulated transcription factors (CCAAT/enhancer binding protein β, CCAAT/enhancer binding protein α) and PPARγ, suppress PPARs, A-FABP and FASN and inhibit 3T3-L1 fibroblast differentiation to adipocytes                                                                                                                                                                                                                                                                                           ([@B144])

  Berberine (BBR)                                               Mitochondria isolated from the liver of high-fat-fed rats   ↓capacity to accumulate calcium and OXPHOS capacity (MMP, oxygen consumption, and cellular ATP levels). ↑ mitochondrial SirT3 activity, normalizing mitochondrial function, and preventing a state of energetic deficit caused by impaired OXPHOS                                                                                                                                                                                                                                                         ([@B231])

  Berberine (BBR)                                               C2C12 cell line                                             Reverted mitochondrial dysfunction induced by HFD and hyperglycemia in skeletal muscle, in part due to an ↑ in mitochondrial biogenesis. The prevention of mitochondrial dysfunction, ↑ in mitochondrial biogenesis, and BBR-induced AMPK activation, are blocked in cells in which SIRT1 has been knocked down.                                                                                                                                                                                          ([@B90])

  Berberine (BBR)                                               Cultured human\                                             ↑ InsR mRNA and ↑ protein expression in dose- and time-dependent results. InsR expression in the L6 rat skeletal muscle cells. BBR-enhanced InsR expression improved cellular glucose consumption only in the presence of insulin. Silencing InsR gene with small interfering RNA or blocking the pi3k ↓ this effect. BBR-induced InsR gene expression through a PKC-dependent activation of its promoter. Inhibition of PKC abolished BBR-caused InsR promoter activation and InsR mRNA transcription.   ([@B148])
                                                                liver and L6 rat skeletal muscle cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Berberine (BBR)                                               3T3-L1 preadipocytes                                        Inhibitor of PPARγ and α                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ([@B107])

  Berberine (BBR)                                               Human platelet                                              Inhibited platelet aggregation, superoxide production *via* modulating AR, NOX, and glutathione reductase activities in HG                                                                                                                                                                                                                                                                                                                                                                                ([@B186])

  Berberine (BBR)                                               Primary hepatocytes                                         Promotion of glucose uptake and prevention of gluconeogenesis by inhibition of SIRT3, and by regulation of mitochondria-related pathways.                                                                                                                                                                                                                                                                                                                                                                 ([@B268])

  Berberine (BBR)                                               HepG2 and mouse primary hepatocytes                         Prolonged activation of AMPK BBR-induced ↑CD36 expression in hepatocytes, evoking in FA uptake *via* processes associated to hepatocellular lipid accumulation and fatty liver.                                                                                                                                                                                                                                                                                                                           ([@B52])

  Berberine (BBR)                                               H9c2 cardiomyocytes                                         Attenuation of palmitate-induced reduction in glucose uptake and consumption by ↓cellular DAG levels and accumulation of TAG.                                                                                                                                                                                                                                                                                                                                                                             ([@B48])

  Berberine (BBR)                                               Rat MCs                                                     Inhibition of mesangial cell proliferation and hypertrophy by modulating cell cycle progress. Suppression of high glucose-induced TGF-β1 and FN expression through blocking NF-κB/AP-1 pathways.                                                                                                                                                                                                                                                                                                          ([@B151])

  Berberine (BBR)                                               human hepatoma\                                             Upregulated LDLR expression independent of sterol regulatory element-binding proteins, but dependent on ERK activation. Also ↑ LDLR expression through a post-transcriptional mechanism that stabilizes the mRNA.                                                                                                                                                                                                                                                                                         ([@B146])
                                                                cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Berberine (BBR)                                               Omental adipose tissue biopsies                             Inhibition of human preadipocyte differentiation and leptin and adiponectin secretion accompanied by downregulation of PPARγ2, C/EBPα, adiponectin, and leptin mRNA expression                                                                                                                                                                                                                                                                                                                            ([@B256])

  Berberine (BBR)                                               3T3-L1 adipocytes, L6 myotubes, and L6 cells                ↑AMPK in 3T3-L1 adipocytes and L6 myotubes, ↑GLUT4 translocation in L6 cells in a pi3k -independent manner, and ↓ lipid accumulation in 3T3-L1 adipocytes                                                                                                                                                                                                                                                                                                                                                 ([@B153])

  Berberine (BBR)                                               CEM, HCT-116,\                                              ↑gene expression of the insulin receptor                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ([@B265])
                                                                HepG2.2.15, SW1990,\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                HT1080 and 293T cell lines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Berberine (BBR)                                               L929 cells                                                  Activation of GLUT 1 transporter                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ([@B58])

  Berberine (BBR                                                3T3-L1 and L6 cells                                         Inhibition of PTP1B, and ↑IR and ↑IRS1 phosphorylation                                                                                                                                                                                                                                                                                                                                                                                                                                                    ([@B49])

  Berberine (BBR)                                               3T3-L1 cells                                                ↓TG accumulation by ↑pIRS1-PI3KpAkt, ↑GLUT4 translocation and ↑insulin tropic action by pCREB-pIRS2-pAkt                                                                                                                                                                                                                                                                                                                                                                                                  ([@B145])

  Berberine (BBR)                                               L6 cells                                                    ↑AMPK and ↑p38 MAPK phosphorylation                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ([@B51])

  Berberine (BBR)                                               3T3-L1 cells                                                Regulation of PPARs and positive transcription elongation of factor b expression                                                                                                                                                                                                                                                                                                                                                                                                                          ([@B271])

  Berberine (BBR)                                               HepG2 and C2C12 cells                                       ↑glucose metabolism by glycolysis stimulation and mitochondrial respiratory chain inhibition                                                                                                                                                                                                                                                                                                                                                                                                              ([@B253])

  Berberine (BBR)                                               HL-7702, normal\                                            LDLR up-regulation by AMPK-dependent Raf-1 activation                                                                                                                                                                                                                                                                                                                                                                                                                                                     ([@B155])
                                                                human liver cell lines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  **Combination of berberine and/or derivatives**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine (BBR) and dihydroberberine                          L6 and LKB1−/− cells                                        AMPK activation, by complex I inhibition of the mitochondrial transport chain                                                                                                                                                                                                                                                                                                                                                                                                                             ([@B235])

  9-*O*-lipophilic group substituted) berberine (9-*O*-BBR)     HepG2 cells                                                 ↑ hypoglycemic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ([@B267])

  13-Methylberberine (13-Me-BBR)                                Mouse 3T3-L1 cells                                          Downregulated the expression of adipocyte differentiation transcription factors (PPARγ and C/EBPα). ↓PPARγ, ↓C/EBPα, and ↓SREBP-1 protein levels. Effect require AMPK signaling pathway                                                                                                                                                                                                                                                                                                                   ([@B54])

  Berberine (BBR) and metformin                                 HepG2 hepatocytes and C2C12 myotubes                        Promotion of glucose metabolism *via* stimulation of glycolysis, not be related to AMPK activity.                                                                                                                                                                                                                                                                                                                                                                                                         ([@B252])

  BBR derivatives: thalifendine                                 Human HepG2 liver cells                                     ↑LDLR or InsR protein expression.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ([@B240])

  BBR amide derivatives                                         HL-7702 cells                                               ↑ glucose-lowering efficacies                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ([@B201])

  Mannose modified berberine (m-BBR)                            HepG2 cells                                                 ↑ antidiabetic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ([@B101])

  Pseudoberberine\                                              HepG2 cells                                                 AMPK activation and LDR up-regulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ([@B241])
  (pBBR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Palmatine                                                     Differentiated myocytes, L6 cells                           anti-diabetic activity may be mediated through insulin dependent pathway by the activation of IRTK and PI3K                                                                                                                                                                                                                                                                                                                                                                                               ([@B206])

  ***Berberis* extracts**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *B aristata* bark methanolic extract                          Dipeptidyl peptidase IV                                     Inhibition of dipeptidyl peptidase IV activity                                                                                                                                                                                                                                                                                                                                                                                                                                                            ([@B40])

  *B. mycrophylla* roots ethanolic extract                      non-resistant and insulin-resistant HepG2 cells             hypoglycemic effects and ↑ glucose uptake by activating AMPK protein.                                                                                                                                                                                                                                                                                                                                                                                                                                     ([@B88])

  *B. vulgaris* roots (ethanolic extract) and berberine (BBR)   α-Glucosidase                                               ↑ α-glucosidase activity, extract \> BBR                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ([@B1])

  *B. vulgaris* roots (methanolic extract)                      α-Amylase                                                   ↑ α-amylase activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ([@B34])

  Jinqi Jiangtang tablet (berberine-contain)                    α-Glucosidase, lipase and aldose                            ↑α-glucosidase, ↑lipase, and ↑aldose reductase activities,                                                                                                                                                                                                                                                                                                                                                                                                                                                ([@B47])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The ↑ and ↓ signs shows significant increase and significant decrease of evaluated factors during mentioned studies.

Studies in mouse 3T3-L1 cells suggested that BBR has an pivotal role in regulating adipose tissues ([@B144]). Experiments in mitochondria isolated from the liver of high-fat-fed rats have shown that BBR exhibited protective effects against MS that was associated with the increased mitochondrial sirtuin-3 (SIRT3) activity, normalizing mitochondrial function, and preventing a state of impaired oxidative phosphorylation (OXPHOS) that caused energetic deficit ([@B231]). In the same way, the preventive effects of BBR on diet-induced insulin resistance (InsR) was suggested to be linked to sirtuin-1 (SIRT1) and mitochondrial biogenesis ([@B90]). It has been suggested that BBR is a unique natural medicine against insulin resistance in T2DM and MS ([@B148]). Different investigations have concluded that BBR as a new hypolipidemic drug works by a different mechanism of action to that of statin drugs ([@B146]). BBR works on multiple molecular targets as an inhibitor of peroxisome proliferator-activated receptor (PPAR) γ and α and is a potential weight reducing, hypolipidemic, and hypoglycemic agent ([@B107]). Prolonged activation of AMP-activated protein kinase (AMPK) by BBR improved CD36 expression in hepatocytes and was evoked in fatty acid uptake *via* processes associated with hepatocellular lipid accumulation ([@B52]). Also, BBR improved insulin sensitivity (InsS) by inhibiting fat storage and adjusting the adipokine profile in human preadipocytes ([@B256]). The hypoglycemic effects of BBR have also been attributed to its acute activation of the transport activity of glucose transporter 1 (GLUT1) ([@B58]).

Numerous studies of BBR in *in vitro* models have shed light on its positive effect on T2DM. BBR promoted glucose uptake and inhibited gluconeogenesis by inhibiting SIRT3, and regulating the mitochondria-related pathways ([@B268]). BBR treatment attenuated a palmitate-induced reduction in glucose uptake and consumption through a reduction in cellular diacylglycerol (DAG) levels and the accumulation of triacylglycerol (TAG) in H9c2 cells ([@B48]). In addition, BBR displayed beneficial effects in the treatment of diabetes and obesity *via* stimulation of AMPK activity ([@B153]). The mechanisms of action of BBR in treatment of T2DM are suggested to be different than that of metformin and rosiglitazone ([@B265]). BBR, as an insulin signal activator, had shown insulin-mimicry effects through the inhibition of protein tyrosine phosphatase 1B (PTP1B) activity on both adipocytes and myocytes ([@B49]) and acted as an effective insulin sensitizing and insulinotropic agent ([@B145]). Moreover, BBR and metformin promoted glucose metabolism by stimulating glycolysis through the inhibition of mitochondrial respiratory chain complex I and independent of AMPK activation ([@B253]). Besides, BBR circumvented the insulin signaling pathways and stimulated the glucose uptake through the AMP-AMPK-p38 MAPK pathway ([@B51]). BBR modulated metabolism-related PPARs expression and differentiation-related positive transcription elongation factor b (P-TEFb) expression in adipocytes, which are associated with its hypoglycemic and hypolipidemic effects ([@B271]). In addition, BBR upregulated LDL receptor expression through Ras-independent (but AMPK-dependent) Raf-1 activation in liver cells ([@B155]). BBR and metformin induced glycolysis and glucose consumption but are not related to the AMPK status ([@B252]).

Different natural and synthetic derivatives of berberine are also evaluated for their *in vitro* activities. A BBR derivative, thalifendine, showed upregulatory activities for both LDLR and InsR, proving to be a potential treatment of both hyperlipidemia and hyperglycemia ([@B240]). Similarly, BBR amide derivatives improved the glucose-lowering effects ([@B201]). Mannose-modified BBR derivative exhibited high anti-diabetic activity at both high and low drug concentrations ([@B101]). Palmatine showed anti-diabetic activity mediated through an insulin-dependent pathway by the activation of IRTK and PI3K ([@B206]). Pseudoberberine (pBBR) has exhibited a potential effect on AMPK activation and LDLR upregulation as compared with BBR ([@B241]).

In the same way, the effects of extracts of species of the genus *Berberis* have been studied in several *in vitro* models and found effective. For instance, *B. mycrophylla* root extracts showed hypoglycemic effects and stimulated glucose uptake in HepG2 cells with and without resistance by activating AMPK protein ([@B88]). *B. aristata* bark methanolic extracts also inhibited the dipeptidyl peptidase--IV (DPP-IV) enzyme activity ([@B40]). *B. vulgaris* roots (ethanolic extract) and BBR showed α-glucosidase inhibition, where the inhibition caused by the extract was found to be higher than that of the BBR alone ([@B1]), and the extract also showed α-amylase inhibition activity ([@B34]).

Some of the mechanisms of *Berberis* species and BBR against diabetes and metabolic diseases are depicted in [**Figure 4**](#f4){ref-type="fig"}.

![The mechanism of action of extracts and its major isolated alkaloid of *Berberis* species in the treatment of diabetes and metabolic syndrome. *Berberis* spp. and berberine upregulate the anti-oxidant enzymes while decreasing reactive oxygen species and inflammatory mediators which in turn decreases oxidative and inflammatory stresses and thus decreasing insulin resistance. Upstream regulating expression of GLUT4, PPARγ, MAPK and downstream regulation of resistin, PPARα results glucose and lipid metabolism moderation. Increase in AMPK and glucokinase activities while decrease in glucose-6-phosphate activity results in decreasing gluconeogenesis, restoring hepatic glycogen and blood glucose. Upregulating AMPK and p38 MAPK activities also cause increasing insulin action and decreasing lipid synthesis. Antiproliferative action and vasorelaxation results in cardioprotection whereas decrease in fibrinogen and thrombin results in increasing fibrinogen and thrombin time respectively. Increasing expression of fatty acid transport proteins, fatty acid beta oxidase and LDLR aids in regulating blood lipid levels.](fphar-11-00041-g004){#f4}

*In Vivo* Activities Against Diabetes and Metabolic Diseases {#s7}
============================================================

Extracts of *Berberis* species and their components, especially alkaloids, have been documented for their potential activity against T2DM and MS in *in vivo* models ([**Table 3**](#T3){ref-type="table"}). In the MS condition, BBR improved vascular inflammation and remodeling that was found to be correlated with the ability to inhibit p38 MAPK activation, ATF-2 phosphorylation, and MMP-2 expression ([@B156]). Long-term treatment with BBR diminished the adipose tissue weight and decreased the renal injury (MS related diseases) in spontaneously hypertensive rats ([@B144]). In normal diet-fed mice treated with BBR, hepatic CD36 expression and TG levels were increased; however, these effects were prevented when hepatic CD36 was silenced with an adenovirus containing CD36-specific short hairpin RNAs (shRNA) ([@B52]). BBR also improved the insulin-mediated vasodilatation of mesenteric arteries in diabetic rats through upregulation of insulin receptor-mediated signaling and increasing vascular InsS ([@B89]). Similarly, BBR increased both InsR and the low-density lipoprotein receptor (LDLR) expression, which resulted in a cellular response against InsR ([@B148]). In hyperlipidemic hamsters, the cholesterol-lowering effect of BBR was found to be due to its activity on upregulation of hepatic LDLR ([@B146]). Administration of BBR in hyperlipidemic and InsR rats decreased blood free fatty acid levels and increased the activity of lipoprotein lipase, leading to the amelioration of blood lipid and glucose metabolism ([@B102]). BBR administration resulted in the decrease of fasting blood glucose (FBL) level and ameliorated glycogen structural fragility ([@B160]). Furthermore, BBR displayed beneficial effects in the treatment of obesity, and this was in part *via* improvement of adipose tissue fibrosis ([@B246]). BBR was reported to act in the liver to regulate lipid utilization and to maintain whole-body energy metabolism by mediating autophagy and FGF21 activation ([@B226]). Additionally, BBR is also reported to reduce the systemic low-grade inflammation of T2DM mice to alleviate disease, and this effect may be achieved through regulating the gut microbes or inhibiting the TLR4 signaling pathway ([@B39]). Other *in vivo* investigations also showed the hypoglycemic effects of BBR through the improvement in gut-derived hormones and the attenuation of both intestinal mucosal mechanic and immune barrier damages ([@B91]). In the same way, the gut microbiota modulation was also suggested to be an effective mechanism of the antidiabetic effect of BBR ([@B100]). The lipid-lowering effect of BBR chloride treatment in hyperlipidemic rats was found to be associated with a global change in the metabolism of lipids, carbohydrates, and amino acids as well as the structure of microbiota ([@B157]).

###### 

*In vivo* activity extracts and/or isolated compounds from *Berberis* species against diabetes and metabolic diseases.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Extracts from *Berberis* spp./isolated compounds                                                                                  Model                                      Outcomes                                                                                                                                            References
  --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Berbamine (BBA)                                                                                                                   STZ-induced diabetic Sprague-Dawley rats   ↑metabolic enzymes activities and preserved the glucose homeostasis                                                                                 ([@B46])

  Berberine (BBR)                                                                                                                   Specific-pathogen-free male C57BL/6 mice   prolonged activation of AMPK BBR-induced ↑CD36 expression and fatty acid uptake                                                                     ([@B52])

  Berberine (BBR)                                                                                                                   male Sprague--Dawley diabetic rats         ↑DVIS and ↑mesenteric vasodilatation by insulin receptor-mediated signaling upregulation.                                                           ([@B89])

  Berberine (BBR)                                                                                                                   male Wistar rats                           ↓secretion of inflammatory factors and ↑vascular remodeling. Inhibition of p38 MAPK activation, ATF-2 phosphorylation, and MMP-2 expression.        ([@B156])

  Berberine (BBR)                                                                                                                   Male spontaneously\                        ↓BWG, ↓retroperitoneal adipose tissues, ↓mesenteric adipose tissues, and ↓urinary albumin excretion.                                                ([@B144])
                                                                                                                                    hypertensive rats                                                                                                                                                                              

  Berberine (BBR)                                                                                                                   T2DM STZ-induced Wistar rats               ↓FBGL, ↓FSIL, ↑InsS, ↑InsR-mRNA, and ↑PKC activity in the liver.                                                                                    ([@B148])

  Berberine (BBR)                                                                                                                   hyperlipidemic hamsters                    ↓TC, ↓LDL-C, ↑hepatic LDLR mRNA, and ↑hepatic LDLR protein                                                                                          ([@B146])

  Berberine (BBR)                                                                                                                   Hyperlipidemic and IR rats                 ↓TC, ↓TG, ↓ApoB, ↓LDL-C, ↓FFA,\                                                                                                                     ([@B102])
                                                                                                                                                                               ↑HDL-C, ↑ISI, ↑ApoAI, and ↑lipoprotein lipase activity                                                                                              

  Berberine (BBR)                                                                                                                   T2DM db/db mice                            ↓FBGL and ameliorated glycogen structural fragility                                                                                                 ([@B160])

  Berberine (BBR)                                                                                                                   HFD Obese rats                             ↓BWG, ↑glucose tolerance, ↓collagen deposition and reversed the upregulation of fibrosis related genes in the adipose tissue of HFD.                ([@B246])

  Berberine (BBR)                                                                                                                   Liver-specific SIRT1 knockout mice         Regulation of lipid usage and preserved whole-body energy metabolism *via* autophagy and FGF21 activation.                                          ([@B226])

  Berberine (BBR)                                                                                                                   Rat islets                                 Inhibition of glucose-stimulated insulin secretion with AMPK activation, ↓OCR\                                                                      ([@B28])
                                                                                                                                                                               and ↓ATP production induced by high glucose, and attenuation of glucose-stimulated expression of fatty acid synthase                                

  Berberine (BBR)                                                                                                                   T2DM mice                                  ↓systemic low-grade inflammation to alleviate disease, by regulating the gut microbes and/or inhibiting TLR4 signaling pathways.                    ([@B39])

  Berberine (BBR)                                                                                                                   Diabetic rats                              hypoglycemic effects associated to ↑ gut-derived hormones.                                                                                          ([@B91])

  Berberine (BBR)                                                                                                                   T2DM rats                                  ↓MALA, ↑InsR and ↑liver enzymes by                                                                                                                  ([@B17])

  Berberine (BBR)                                                                                                                   Diabetic rats                              Attenuation of hyperglycemia, oxidative stress and inflammation by potentiation of the antioxidant defenses and up-regulation of PPARγ expression   ([@B166])

  Berberine (BBR)                                                                                                                   SD rats                                    ↓2h-PPG level by local inhibition of intestinal DPP-IV.                                                                                             ([@B243])

  Berberine (BBR)                                                                                                                   Diabetic rat model                         ↓ expressions of Nrf2 and HO-1                                                                                                                      ([@B230])

  Berberine (BBR)                                                                                                                   Diabetic rats                              Inhibition of hepatic gluconeogenesis *via* the regulation of the LKB1-AMPK-TORC2 signaling pathway.                                                ([@B115])

  Berberine (BBR)                                                                                                                   Diabetic hamsters                          ↓BGL, ↓TC, ↓TG, ↓FFA, ↓LDL-C, ↓Glucose, ↓insulin levels, ↓malondialdehyde, ↓thiobarbituric acid-reactive substance, and ↓8-isoprostane\             ([@B164])
                                                                                                                                                                               levels, ↑expression of skeletal muscle glucose transporter 4 mRNA and ↓liver\                                                                       
                                                                                                                                                                               LDL receptor mRNA expression.                                                                                                                       

  Berberine (BBR)                                                                                                                   Zucker Diabetic\                           ↓HbA1c, ↓TC, ↓TG, ↑insulin secretion,\                                                                                                              ([@B77])
                                                                                                                                    Fatty Rats                                 regulation of glucose and lipid metabolism and activation of pAMPK.                                                                                 

  Berberine (BBR)                                                                                                                   db/db mice and high-fat--fed Wistar rats   ↓BWG, ↑glucose tolerance, ↓TG, and ↑ insulin action                                                                                                 ([@B153])

  Berberine (BBR)                                                                                                                   Diabetic rats                              Direct inhibition of liver gluconeogenesis                                                                                                          ([@B251])

  Berberine (BBR)                                                                                                                   Diabetic rats                              Intestinal microbiome modulation                                                                                                                    ([@B100])

  Berberine (BBR)                                                                                                                   Diabetic rats                              Lipid metabolism regulation and ↑ elimination of free radicals                                                                                      ([@B229])

  Berberine (BBR)                                                                                                                   Diabetic rats                              PPAR α/δ up-regulation and PPARδ repression in liver                                                                                                ([@B272])

  Berberine (BBR)                                                                                                                   Non-obese Diabetic rats                    Regulation of MAPK activity to control the differentiation of Th17 and Th1                                                                          ([@B59])

  Berberine (BBR)                                                                                                                   Diabetic rats                              Promotes secretion of glucagon-like peptide type I                                                                                                  ([@B165])

  Berberine (BBR)                                                                                                                   Diabetic rats                              Tyrosine phosphatase 1B activity inhibition and insulin-like effect                                                                                 ([@B49])

  Berberine (BBR)                                                                                                                   Diabetic hamster                           Up-regulation of LXRα, PPARα, and down-regulation of SREBPs                                                                                         ([@B163])

  Berberine (BBR)                                                                                                                   Diabetic rats                              ↓ intestinal disaccharidases and β-glucuronidases activities                                                                                        ([@B162])

  Berberine (BBR)                                                                                                                   Diabetic rats                              Glucose metabolism modulation by GnRH-GLP-1 and MAPK pathway in the gut                                                                             ([@B266])

  Berberine chloride (BC)                                                                                                           Diabetic rats                              ↓FBG, ↓WBC, ↓HbAlc ↑plasma insulin, ↑hemoglobin, ↑RBC, ↑Ht, ↑MCH and ↑MCHC.                                                                         ([@B43])

  Berberine chloride (BC)                                                                                                           Diabetic rats                              ↓TC, ↓TG, ↓phospholipids, ↓LDL-C, ↓VLDL, ↓LOOH, ↓TBARS. ↑SOD,\                                                                                      ([@B44])
                                                                                                                                                                               ↑CAT, ↑GPx, non-enzymatic antioxidant (↑GSH, ↑vitamin C, ↑vitamin E) and ↑IRS-1, ↑PKB, ↑Akt and ↑GLUT-4)                                            

  Berberine fumarate (BF)                                                                                                           T2DM rats                                  ↑metabolic disorder and ↓ inflammation by ↓over-expression of TLR4 and p-JNK and ↑PI3K and VGLUT2 expression.                                       ([@B60])

  **Combination of berberine and other compounds/extracts**                                                                                                                                                                                                                                                                        

  Berberine chloride (BC), oryzanol and vitamin B2                                                                                  Male Wistar hyperlipidemic rats            ↓lipid effect without apparent adverse side effects.                                                                                                ([@B157])

  Berberine (BBR), *Ortosiphon staminensis*,\                                                                                       Rats                                       ↓TC, ↓LDL-C, ↓DBP, ↓TG, and ↑HDL-C. antihypertensive effect, which allows an effective control of blood pressure                                    ([@B203])
  policosanol, red yeast rice extract, folic acid and coenzyme Q10                                                                                                                                                                                                                                                                 

  Berberine - Metformin Hybrid (BMH473)                                                                                             T2DM obese rats                            ↑maintaining glucose and ↑ lipid homeostasis, ↑antihyperlipidemic activity.                                                                         ([@B114])

  berberine (BBR) and Timosaponin B2 (TB-2)                                                                                         Goto-Kakizaki rats                         ↑anti-diabetic efficacy.                                                                                                                            ([@B108])

  berberine (BBR) and Glycyrrhizic acid                                                                                             Rats                                       ↓FBG, and ↑Insulin level                                                                                                                            ([@B191])

  Berberine (BBR) with resveratrol                                                                                                  High fat diet-induced mice                 ↓TC, ↓TG, and ↓LDL-C                                                                                                                                ([@B273])

  Berberine (BBR) and Gelucire44/14                                                                                                 diabetic mice                              Gelucire44/14 showed potential ↑oral absorption of BBR thus ↑ anti-diabetic efficacy.                                                               ([@B225])

  Berberine organic acid salts (BOAs), including berberine citrate, berberine fumarate, berberine malate, and berberine succinate   T2DM rats                                  ↑ hypoglycemic effects                                                                                                                              ([@B158])

  Berberine (BBR) and *Coptis chinensis* extract (CCE)                                                                              T2DM rats                                  ↑pancreatic insulin secretion *via* ↑ islet β-cell proliferation and ↑ protein expression of PARP-1.                                                ([@B116])

  Berberine (BBR) combined with Canagliflozin                                                                                       Diabetic mice                              ↓FBG and ↓insulin. Antidiabetic effect associated with ↑ pAMPK and ↓ TNFα in kidneys.                                                               ([@B37])

  Berberine (BBR) and Ginsenoside Rb1 (Rb1)                                                                                         Diabetic mice                              Improved abnormal metabolism of glucose and lipid.                                                                                                  ([@B212])

  Berberin glycyrrhizinate complex salt (BGC)                                                                                       GK rats                                    ↓PBG, ↓insulin level, ↓GSP, ↓LDL-C and ↓MDA, and ↑ histopathological changes in kidney and pancreas.                                                ([@B242])

  ***Berberis* extracts**                                                                                                                                                                                                                                                                                                          

  *B. aristata* roots\                                                                                                              Diabetic rats                              ↓dose-dependent in hyperglycemia, ↓TC, ↓TG, ↓AST, and ↓ALT levels of serum, ↓serum creatinine and ↓blood urea.                                      ([@B176])
  (ethanolic extract)                                                                                                                                                                                                                                                                                                              

  *B. aristata* stem\                                                                                                               T1DM and T2DM albino rats                  ↑Liver glycogen and ↓FBS                                                                                                                            ([@B195])
  (ethanolic extract)                                                                                                                                                                                                                                                                                                              

  *B. aristata* roots\                                                                                                              STZ-induced diabetic rats                  ↓PBG                                                                                                                                                ([@B184])
  (ethanolic extract)                                                                                                                                                                                                                                                                                                              

  *B. aristata* stem bark\                                                                                                          STZ-induced diabetic rats                  ↓TC and ↑HDL-C                                                                                                                                      ([@B5])
  (aqueous extract)                                                                                                                                                                                                                                                                                                                

  *B. aristata* bark (ethanolic extract)                                                                                            alloxan-induced diabetic rats              ↓PBG                                                                                                                                                ([@B208])

  *B. aristata* stem bark (methanolic extract)                                                                                      Alloxan-Induced DiabeticRats               ↓PBG                                                                                                                                                ([@B98])

  *B. aristata* roots (methanolic-water extract                                                                                     Diabetic rabbits                           ↓PBG                                                                                                                                                ([@B12])

  *B. aristata* roots\                                                                                                              Diabetic rats                              Regulated glucose homeostasis *via* ↓ gluconeogenesis and ↓oxidative stress.                                                                        ([@B217])
  (water-ethanolic extract)                                                                                                                                                                                                                                                                                                        

  *B asiatica* roots (water-ethanolic extract)                                                                                      Diabetic rats                              ↓BW                                                                                                                                                 ([@B216])

  *B. dictyophylla* roots (extract)                                                                                                 Diabetic mice and normal mice              ↓FBG, ↓ICAM-1, ↓ANGII, and ↓SOD in serum expression                                                                                                 ([@B260])

  *B. holstii* roots\                                                                                                               Alloxan-induced\                           ↓FBGL                                                                                                                                               ([@B143])
  (aqueous extract)                                                                                                                 diabetic male mice                                                                                                                                                                             

  *B. integerrima* roots\                                                                                                           Diabetic male Wistar rats                  ↑renal by control of blood glucose and renal protective effects.                                                                                    ([@B24])
  (aqueous extract)                                                                                                                                                                                                                                                                                                                

  *B. integerrima* fruits (anthocyanin fraction)                                                                                    Diabetic Male Sprague Dawley rats          ↓FBG, ↑ liver glycogen level, and ↑ body weight.                                                                                                    ([@B205])

  *B. julianae* roots (methanolic extract)                                                                                          T2DM mice                                  ↑ GLUT4 translocation, ↑ oral glucose tolerance, ↑LDL-C, ↓BWG, ↓blood glucose and ↓other related blood-lipid contents.                              ([@B257])

  *B. lycium* roots\                                                                                                                Diabetic rabbits                           ↓ FBG.                                                                                                                                              ([@B7])
  (aqueous extract)                                                                                                                                                                                                                                                                                                                

  *B. lycium* extract (BLE)                                                                                                         Diabetic rabbits                           ↓TG, ↓TC, ↓LDL-C, and ↑HDL-C                                                                                                                        ([@B8])

  *B. lycium* leaves\                                                                                                               Female diabetic rabbits                    ↓FBG                                                                                                                                                ([@B109])
  (methanolic extract)                                                                                                                                                                                                                                                                                                             

  *B. lycium* roots\                                                                                                                Alloxan treated rats                       ↓FBG                                                                                                                                                ([@B96])
  (ethanolic extract)                                                                                                                                                                                                                                                                                                              

  *B. lycium* roots (powder)                                                                                                        Broilers chickens                          ↓TG, ↓TC, ↓LDL-C, and ↑HDL-C                                                                                                                        ([@B42])

  *B. lycium* roots (aqueous extract)                                                                                               Diabetic rats                              ↓FBG, ↓TC, ↓TG, ↓LDL-C, ↓VLDL, ↓SGOT, ↓SGPT, and ↓ALP                                                                                               ([@B179])

  *B. lycium* fruits\                                                                                                               Diabetic rats                              ↓TC, ↓TG, ↓LDL-C, ↓VLDL, and ↓MDA                                                                                                                   ([@B193])
  (aqueous extract)                                                                                                                                                                                                                                                                                                                

  *B. lycium* root (methanolic extract) and berberine (BBR)                                                                         Diabetic rats                              ↓FBG, ↑glucose tolerance, positive serum lipid profiles, glycosylated hemoglobin and body weight.                                                   ([@B97])

  *B. vulgaris* roots (aqueous extract)                                                                                             Diabetic rats                              ↓TC and ↓TG.                                                                                                                                        ([@B170])

  *B. vulgaris* fruits\                                                                                                             T1DM Rats                                  ↑ serum glucose levels, ↑ serum alanine aminotransferase activities, and ↓ HbA1c.                                                                   ([@B118])
  (aqueous and hydro-ethanolic extract)                                                                                                                                                                                                                                                                                            

  *B. vulgaris* fruits\                                                                                                             Diabetic rats                              ↑total antioxidant levels, ↓MDA and ↓FBG, and ↑mRNA level of GK                                                                                     ([@B103])
  (ethanolic extract)                                                                                                                                                                                                                                                                                                              

  *B. vulgaris* fruits\                                                                                                             Diabetic rats                              ↓ liver damage by influencing hepatic\                                                                                                              ([@B194])
  (Hydro-ethanolic extract)                                                                                                                                                    histopathological and biochemical markers                                                                                                           

  Jatrorrihizine                                                                                                                    Hyperglycemic mice                         ↓FBG and ↑aerobic glycolysis                                                                                                                        ([@B254])

  Jatrorrihizine and berberine                                                                                                      Diabetic rats                              ↓FBG. Berberine \> Jatrorrihizine                                                                                                                   ([@B87])

  Palmatine                                                                                                                         Normal rats                                ↓FBG.                                                                                                                                               ([@B185])
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The ↑ and ↓ signs show significant increase and significant decrease, respectively, of evaluated factors during mentioned studies.

On the other hand, BBR protects against metformin-associated lactic acidosis (MALA) in streptozotocin (STZ)-induced T2DM ([@B17]). BBR attenuated hyperglycemia and its associated oxidative stress and inflammation through, possibly, the potentiation of the antioxidant defenses and upregulation of PPARγ expression ([@B166]). BBR decreased 2-hour postprandial plasma glucose (2h-PPG) level in STZ-induced diabetic rats by locally inhibiting intestinal DPP-IV ([@B243]). Moreover, BBR also reduced the blood glucose level in diabetic rats, improving the blood lipid and decreasing the retinal vascular injury, suggesting its association with the reduced expressions of Nrf2/HO-1 ([@B230]). BBR also upregulated protein expressions of LKB1, AMPK, p-AMPK, and p-TORC2 and also inhibited the translocation of TOCR2 into the cell nucleus ([@B115]). Moreover, BBR was also found to be effective in lowering blood glucose and lipid levels, reducing the body weight, and alleviating the oxidative stress in diabetic hamsters ([@B164]).

The anti-diabetic effect of BBR was suggested to be mainly due to its activity in the regulation of glycometabolism and lipometabolism and the activation of AMPK ([@B153]; [@B77]). BBR improved glucose metabolism through an insulin-independent pathway ([@B251]). BBR also significantly inhibited the progression of diabetes induced by alloxan, and the effect of BBR on diabetes was suggested to be associated with its hypoglycemic effect, modulating lipids metabolic effects and its ability to scavenge free radicals ([@B229]). BBR improved glucolipid metabolism in diabetic rats both in the blood and liver, possibly through modulating the metabolic related PPARα/δ/γ protein expression in liver ([@B272]). BBR targeted MAPK to suppress Th17 and Th1 differentiation in T1DM NOD mice and showed a novel role of ERK in Th17 differentiation through downregulation of STAT3 phosphorylation and RORt expression ([@B59]). Altered hepatic SREBPs, LXRα, and PPARα transcriptional programs were suggested to be involved in the therapeutic mechanisms of BBR on fat-induced hepatic insulin resistance (FIHIR) in T2DM hamsters ([@B163]). The inhibitory effect on intestinal disaccharidases and *β*-glucuronidase of BBR might be one of the mechanisms for BBR as an antihyperglycaemic agent ([@B162]). BBR caused the glucose metabolism modulation by the GnRH-GLP-1 and MAPK pathway in the gut ([@B266]). The treatment of BBR chloride notably protected the blood components ([@B43]) and significantly reversed the abnormal levels of lipids, oxidant status, and insulin signaling molecules in the diabetic rat model ([@B44]). BBR also reduced the release of lipopolysaccharides and ameliorated inflammation by reducing the level of lipolysaccharide binding protein (LBP), thus alleviating intestinal injury and improving InsR ([@B60]).

The combination of *Ortosiphon staminensis*, policosanol, red yeast rice extract, BBR, folic acid, and coenzyme Q~10~ provided an antihypertensive effect, which allowed for an effective control of blood pressure in patients with MS ([@B203]). The berberine-metformin hybrid compound BMH473 was found to be beneficial for maintaining glucose and lipid homeostasis in T2DM rats, and it exhibited better anthyperlipidaemic effects compared to metformin and BBR alone ([@B114]).

Combining timosaponin B2 (TB-2) and BBR in a single formulation enhanced the anti-diabetic efficacy by improving the intestinal absorption ([@B108]). Glycyrrhizic acid was also reported to improve the oral absorption of BBR by inhibiting P-gp, and it thus increased the anti-diabetic effects of BBR in db/db mice ([@B191]). Lipid-lowering effects of BBR were also reported to be increased with resveratrol, which may be associated with upregulation of a low-density-lipoprotein (LDL) receptor ([@B273]). Similarly, gelucire44/14 was found to enhance the oral absorption of BBR and thus improve the antidiabetic efficacy of BBR ([@B225]). Berberine organic acids (BOAs) were found to be comparable to berberine hydrochloride (BH) in terms of hypoglycaemic effects, they were but superior with regard to safety from hyperchloraemia in T2DM rats ([@B158]). *Coptis chinensis* (containing berberine) and BBR exerted similar effects when used for the treatment of T2MD rats, mainly *via* the stimulation of the pancreatic secretion of insulin ([@B116]). Berberine chloride was a stronger antidiabetic agent than BBR or canagliflozin alone with fewer side effects on kidneys in the diabetic mice ([@B37]). BBR and ginsenoside Rb1 (Rb1) improve abnormal metabolism of glucose and lipid ([@B212]).

Extracts of *Berberis* plants have shown interesting results in *in vivo* models. The ethanolic extract of *B. aristata* showed antidiabetic activity due to its significant dose-dependent reduction effect on the blood glucose levels ([@B208]; [@B176]), which were also reported to be better than glibenclamide ([@B195]) and comparable to metformin in diabetic rats ([@B184]). In addition, the aqueous extract of *B. aristata* showed significant antidiabetic activity, decreased total cholesterol, increased HDL-C levels, and prevented the body weight loss in diabetic rats ([@B5]).

The aqueous extract of *B. lycium* roots showed an antihyperlipidemic effect ([@B8]). *B. lycium* leaf extracts alleviated lipid profile levels and might be used efficiently in hyperglycemic and diabetic patients ([@B109]). Also, the root extract of *B. lycium* reduced the serum glucose levels in normal and diabetic rats ([@B96]). In chicken Broilers, the powder of *B. lycium* reduced the serum cholesterol ([@B42]). The oral administration of extracts of *B. lycium* showed hypoglycemic activity ([@B179]) and alleviated lipid profile levels ([@B193]). Similarly, the methanolic extract of the *B. lycium* root and its main alkaloid BBR showed hypoglycemic activity ([@B97]) and showed antiglycation activity ([@B142]).

On the other hand, in diabetic rats, the beneficial effects of *B. vulgaris* extracts showed positive effects in attenuating the side effects of T2DM ([@B118]), ameliorating oxidative stress ([@B103]), decreasing the liver damage by influencing hepatic histopathological and biochemical markers ([@B194]), and showed that the serum cholesterol and serum triglycerides levels were decreased ([@B170]).

Other species of *Berberis* have also been studied. For instance, *B. asiatica* hydro-ethanolic root extracts have shown to be a potent orally effective antidiabetic extract ([@B216]). Likewise, the *B. dictyophylla* cortex could significantly reduce the level of fasting blood glucose, ICAM-1, and ANG II expression ([@B260]). The *B. holstii* extract showed the reduction of blood glucose levels ([@B143]). Furthermore, the aqueous extract of *B. integerrima* roots improved renal dysfunction in STZ-induced diabetic rats through controlling blood glucose, and it also showed renal protective effects ([@B24]). The anthocyanin fraction of the fruits of *B. integerrima* also showed hypoglycemic effects ([@B205]). Moreover, the methanolic extract of *B. julianae* roots was also reported to possess promising beneficial effects for the treatment of T2DM with the possible mechanism *via* stimulating AMPK activity ([@B257]).

Other alkaloids isolated from *Berberis* species have also shown promising activities against T2DM and MS. For example, berbamine increased the activity of metabolic enzymes and preserved the glucose homeostasis in HFD/STZ induced diabetic rats ([@B46]). Jatrorrihizine (JAT) induced an important decrease in FBG in normal and hyperglycemic mice, attributed to improve in aerobic glycolysis ([@B254]). JAT, BBR, and a combination of BBR and JAT decreased the FBG of diabetic and normal mice at different degrees. JAT also possessed the function of decreasing FBG, which was found less than that of BBR at the same dose level ([@B87]). Palmatine was also found to decrease FBG and suppressed the increase of blood glucose level in normal rats ([@B185]).

Studies in Humans {#s8}
=================

Several pilot studies as well as pre-clinical studies and clinical trials have evaluated the beneficial effects of *Berberis* extracts and isolated compounds on diabetes, metabolic syndrome, and other metabolic diseases ([**Table 4**](#T4){ref-type="table"}).

###### 

Studies in diabetic and/or metabolic syndrome patients using treatment with extract and/or isolated compounds of *Berberis* species.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Berberis* spp./isolated compound                                                                                                                                                                                           Study design/Model                                                                                                                                   Results                                                                                      References
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------
  Berberine\                                                                                                                                                                                                                  MS patients (*n*=80) RCT, 1 month                                                                                                                    ↓FBG, ↓PBG, ↓InsR, ↓TG, ↓TC, ↓hs-CRP, and ↓IL-6 and ↓TNF-α                                   ([@B38])
  (BBR, 0.05g, 4 tablets/time, 3 times/day)                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine (BBR, 0.5 g, 2 times/day)                                                                                                                                                                                         T2DM patients (*n* = 300), double-blind, RCT, 16 weeks                                                                                               ↓FPG                                                                                         ([@B174])

  Berberine\                                                                                                                                                                                                                  MS patients (*n*=24) double-blind, placebo-controlled, RCT, 3 months                                                                                 ↓WC, ↓SBP, ↓TG, ↓AUC of glucose, ↓AUC of insulin, ↓insulinogenic index, and ↑Matsuda index   ([@B183])
  (BBR, 0.5 g, 3 times/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine\                                                                                                                                                                                                                  T2DM patients (*n*=114), RCT, 6 months                                                                                                               ↓HbA1c, ↓BUN, ↓SP, ↓hs-CRP, ↓ESR, and ↓eGFR                                                  ([@B159])
  (BBR, 0.4 g, 3 times/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine\                                                                                                                                                                                                                  Mild mixed hyperlipidemia\                                                                                                                           ↓TC, ↓LDL-C and ↓TG.                                                                         ([@B146])
  (BBR, 0.5 g, 2 times/day)                                                                                                                                                                                                   (*n*=32), double-blind, RCT, 12 weeks                                                                                                                                                                                                             

  Berberine\                                                                                                                                                                                                                  T2DM and mixed hyperlipidemia patients (*n*=116), double-blind, RCT, 3 months                                                                        ↓FPG, ↓PPG, ↓HbA1c, ↓TG, ↓TC, ↓LDL-C, and ↑GDR                                               ([@B264])
  (BBR, 1 g, 1 time/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Berberine\                                                                                                                                                                                                                  Newly diagnosed T2DM patients (*n*=36) double-blind, RCT, 3 months                                                                                   ↓HbA1c, ↓FBG, ↓PBG, ↓TG, ↓TC ↓FPI, ↓IR, and ↓LDL-C.                                          ([@B258])
  (BBR, 0.5 g, 3 times/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine\                                                                                                                                                                                                                  Hyperlipidemic patients (*n* =86), Open study, 3 months                                                                                              ↓LDL-C, ↓TC and ↓TG.                                                                         ([@B269])
  (BBR, 0.5 g, 2 times/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine (BBR, 0.3g, 3 times/day)                                                                                                                                                                                          MS patients (*n*=41) Double‐blind, RCT, 3 months                                                                                                     ↓BMI, and ↓leptin levels, ↓leptin/adiponectin ratio, ↓HOMA-IR, and ↑IS                       ([@B256])

  Berberine\                                                                                                                                                                                                                  PCOS and IR patients (*n*=89) randomized, single center, placebo-controlled, 3 months                                                                ↓WHR, ↓TC, ↓TG, ↓LDLC, ↓FPG, ↓HOMA-IR, ↓AUC of insulin, ↑HDLC, and ↑SHBG                     ([@B247])
  (BBR, 0.5 g, 3 times/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine\                                                                                                                                                                                                                  T2DM and dyslipidemic patients (*n* = 116) double-blind, placebo-controlled and multiple-center trial consisting of a screening visit, RCT, 2-week   ↓FFA                                                                                         ([@B93])
  (BBR, 1.0 g, 1 time/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Berberine (BBR, 1.0 g, 1 time/day)                                                                                                                                                                                          T2DM patients with fasting blood glucose (*n* = 96), 2 months                                                                                        ↓FBG, ↓HA1c, ↓TG, and ↓insulin levels                                                        ([@B265])

  Berberine (BBR, 0.5 g, 2 times/day)                                                                                                                                                                                         T2DM patients\                                                                                                                                       ↓FPG, ↓PMBG, and ↓FA.                                                                        ([@B200])
                                                                                                                                                                                                                              (*n*=228) double-blind randomized controlled placebo, 4 weeks                                                                                                                                                                                     

  Berberine\                                                                                                                                                                                                                  T2DM patients (*n*=30), open labelled, observational and single centre study, 12 weeks                                                               ↓FBG, ↓PPBG, and ↓GHb                                                                        ([@B63])
  (BBR, 0.5 g, 2 times/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine\                                                                                                                                                                                                                  T2DM patients (*n*=30), 8 weeks                                                                                                                      ↓BMI, ↓FBG, ↓HbAlc, ↓fasting insulin, ↓TG, ↓TC, ↓HDL-C, ↓LDL-C, ↓CPR, ↓TNF-α, and\           ([@B50])
  (BBR, 0.3 g, 3 times/day)                                                                                                                                                                                                                                                                                                                                                        ↓LPS                                                                                         

  Berberine (BBR, N.I., 2 times/day)                                                                                                                                                                                          T2DM patients (*n*=41), open-label interventional RCT, 3 months                                                                                      ↓HbA1C, ↓FBG, and ↓PPG                                                                       ([@B199])

  Berberine (BBR, 0.3 g, 3 times/day)                                                                                                                                                                                         Mild hyperlipemic patients (*n*=97) Double‐blind, RCT, 3 months                                                                                      ↓TG, ↓TC, and ↓LDL-C                                                                         ([@B244])

  Berberine\                                                                                                                                                                                                                  Hypercholesterolemia in tolerance to more than one statin (*n*=91), 3 months                                                                         ↓ LDL-C and ↓TG.                                                                             ([@B56])
  (BBR, 0.4 g, 1 time/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **Berberine combined with others compounds and extracts**                                                                                                                                                                                                                                                                                                                                                                                                                     

  Berberine\                                                                                                                                                                                                                  Hypercholesterolemic patients (*n*=63), double-blind, RCT, 2 months                                                                                  ↓LDL-C, ↓TC, and ↓TG                                                                         ([@B147])
  (BBR, 1.0 g, 1 time/day.) and simvastatin (SIMVA)                                                                                                                                                                                                                                                                                                                                                                                                                             

  (Berberine, BBR, 0.5 g; red yeast, 200 mg; and policosanol, 10 mg; 1 time/day)                                                                                                                                              Hypercholesterolemic patients (*n*=50), double-blind, single-centered, placebo-controlled, RCT, 6 weeks                                              ↓TC, ↓LDL-C, ↓TG, ↑FMD, and ↑InsS                                                            ([@B4])

  (Berberine, BBR, 0.5 g; policosanols, 10 mg; and red yeast rice, 200 mg; 1 time/day)                                                                                                                                        Hypercholesterolemic patients (*n*=135) randomized, double-blind, EZE-controlled, 6 months                                                           ↓LDL-C, and ↓TG                                                                              ([@B189])

  Armolipid Plus ™ composed by (Berberine, BBR, 0.5 g; red yeast rice, 200 mg; policosanol, 10 mg; folic acid, 0.2 mg; coenzyme Q~10~, 2.0 mg; and astaxanthin, 0.5 mg; 1 time/day)                                           Hypercholesterolemic patients (*n*=106), single-blind, single centered, placebo-controlled, RCT, 12 months                                           ↓TC, ↓LDL-C, and ↓InsR                                                                       ([@B168])

  Armolipid Plus ™ composed by (Berberine, BBR, 0.50g; red yeast rice, 200 mg; policosanol, 10 mg; folic acid, 0.2 mg; coenzyme Q~10~, 2.0 mg; and astaxanthin, 0.5 mg; 1 time/day)                                           Hyperlipidemic patients (*n*=102), double-blind, parallel, controlled, Multiple centered, placebo-controlled, RCT, 12 weeks                          ↓LDL-C, ↓apo B-100, ↓TC/HDL-C, ↓ApoB/ApoA1 ratio, and ↑ApoA1                                 ([@B220])

  Armolipid Plus ™ composed by (Berberine, BBR, 0.5g; red yeast rice, 200 mg; policosanol, 10 mg; folic acid, 0.2 mg; coenzyme Q~10~, 2.0 mg; and astaxanthin, 0.5 mg; 1 time/day)                                            Dyslipidemic patients (*n* = 1751) Double‐blind, RCT, 16 weeks                                                                                       ↓TC and ↓LDL-C                                                                               ([@B234])

  Armolipid Plus ™ composed by (Berberine, BBR, 0.5g; red yeast rice, 200 mg; policosanol, 10 mg; folic acid, 0.2 mg; coenzyme Q~10~, 2.0 mg; and astaxanthin, 0.5 mg; 1 time/day)                                            Hypercholesterolemic patients (*n*=66), single-blind, placebo-controlled, RCT, 3 weeks                                                               ↓TC, ↓LDL-C, and ↓TG                                                                         ([@B92])

  Armolipid Plus ™ composed by (Berberine, BBR, 0.5 g; red yeast rice, 200 mg; policosanol, 10 mg; folic acid, 0.2 mg; coenzyme Q~10~, 2.0 mg; and astaxanthin, 0.5 mg; 1 time/day)                                           Moderate dyslipidemic and MS patients (*n*=30), double-blind, centered, placebo-controlled, RCT,                                                     ↓TC, ↓LDL-C, ↓leptin-to-adiponectin ratio, and ↑HDL-C                                        ([@B204])

  Armolipid Plus ™ composed by (Berberine, BBR, 0.5 g; red yeast rice, 200 mg; policosanol, 10 mg; folic acid, 0.2 mg; coenzyme Q~10~, 2.0 mg; and astaxanthin, 0.5 mg; 1 time/day)                                           Dyslipidemic with ischemic heart disease treated patients (*n*=100), single-blind, EZE-controlled, RCT, 12 months                                    ↓LDL-C, ↓TC, ↓TG, and ↑HDL-C                                                                 ([@B169])

  Berberine (BBR, 500mg) and Armolipid Plus ™\                                                                                                                                                                                Hyperlipidemic patients (*n*=40) single-blind, no placebo-controlled, 4 weeks                                                                        ↓TC, ↓LDL-C, ↓ApoB, ↓TG, and ↑HDL-C                                                          ([@B57])
  Composed by (Berberine, BBR, 0.5 g; red yeast extract, 200 mg; policosanol, 10 mg; folic acid, 200 mg; coenzyme Q~10~, 2 mg; and astaxanthin, 0.5 mg; 1 time/day)                                                                                                                                                                                                                                                                                                             

  Body Lipid ™ composed by (Berberine, BBR, 0.5 g; red yeast rice, 10 mg; coenzyme Q~10~, 2 mg;\                                                                                                                              Hypercholesterolemic patients (*n* = 158) Double‐blind, RCT, 4 weeks                                                                                 ↓TC and ↓LDL-C                                                                               ([@B61])
  and hydroxytyrosol, 5 mg; 1 time/day)                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Berberine (BBR, 0.2g; monacolin K, 3 mg; chitosan, 10 mg; and coenzyme Q~10~, 10 mg; 1 time/day)                                                                                                                            Hypercholesterolemic patients (*n* =36) Double-blind phase II placebo-controlled study, 12 weeks                                                     ↓nHDL-C, ↓LDL-C and ↓apoB                                                                    ([@B221])

  Estromineral lipid ™ composed by (Berberine, BBR, 0.5 g; soy isoflavones, 60 mg; *Lactobacillus sporogenes*, 1x10^9^ spores; calcium phosphate dehydrate, 137 mg; vitamin D~3~, 5 μg; and folic acid, 0.2 mg; 1 time/day)   Menopausal women (*n*=120) RCT, 12 weeks                                                                                                             ↓TC, ↓LDL-C, and ↓TG                                                                         ([@B55])

  Berberine (BBR, 1.0 g; phytosterols, 4 g; antioxidants, 2 capsules; probiotics, 12 billion colony forming units; fish oil, 2g; and soy, pea, and whey proteins, 40 g, 2-3 times/day)                                        CMS patients (*n*=44)\                                                                                                                               ↓body mass, ↓fat mass, ↓TC, ↓LDL-C, ↓TG, ↓TC/HDL-C, ↓TG/HDL-C, ↓apoB/apoA1, and ↓hs-CRP.     ([@B62])
                                                                                                                                                                                                                              open-label, 2-arm, RCT, 13 weeks                                                                                                                                                                                                                  

  Berberine sulfate trihydrate (0.1 g, equiv. 69 mg berberine, BBR); Hop rho iso-alpha acids, 200 mg; vitamin D~3~, 500 IU; and vitamin K~1~ 500 μg; 2 times/day)                                                             MS postmenopausal women patients (*n*=51), randomized, single-blind, 2-arm placebo-controlled, RCT, 14 weeks                                         ↓serum OC, serum ↑25(OH)D, and ↑IGF-I                                                        ([@B150])

  Berberine (BBR, 0.5 g, 3 times/day) and methylglyoxal (0.5 g ×3 times/day)                                                                                                                                                  T2DM patient (*n*=200), case--control study, 3 months                                                                                                ↓HOMA-IR, and ↓MGO                                                                           ([@B171])

  Berberine (BBR, 0.5 g; orthosiphon, 300 mg; red yeast rice, 60 mg; monacolin, 3 mg; policosanol, 10 mg; folic acid, 0.2 mg; and coenzyme Q~10~, 15mg; 1 time/day)                                                           MS patients (*n*=1161), Double-blind, Randomized, controlled, 1 year                                                                                 ↓TC, ↓LDL-C, ↓HDL-C, ↓TG, ↓SBP, and ↓DBP                                                     ([@B167])

  ***Berberis* extracts**                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  *B. aristata* stem powder\                                                                                                                                                                                                  T2DM with dyslipidemic patients (*n*=90) open parallel, RCT, 9 months                                                                                ↓FBS, ↑HDL, ↓TC, ↓TG, and ↓LDL.                                                              ([@B213])
  (1.5 and 3 g in two divided doses daily)                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum* (silymarin, 210 mg) and only *B. aristata* extract (Berberine, BBR, 1.0 g) 2 time/day                                                       T2DM patients (*n*=69), single-blind, RCT, 120 days                                                                                                  ↓IFG, ↓HbA1c, ↓TC, ↓TG, ↓LDL (only Berberol ^®^),\                                           ([@B72])
                                                                                                                                                                                                                                                                                                                                                                                   ↓AST, and ↓ALT                                                                               

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum* (silymarin, 210 mg) 2 times/day                                                                                                             T1DM patients\                                                                                                                                       ↓TIC, ↓HgbA1c, ↓FPG, ↓PPG, ↓TC, ↓TG, ↓LDL-C, and ↑HDL-C                                      ([@B69])
                                                                                                                                                                                                                              (*n*=85) double-blind, randomized, placebo-controlled, 6 months                                                                                                                                                                                   

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum*\                                                                                                                                            Dyslipidemic patients (*n*=105), Double‐blind, RCT, 3 months                                                                                         ↓TC, ↓LDL-C, ↓TG, ↑HDL-C, ↓FPI, and ↓HOMA-IR                                                 ([@B66])
  (silymarin, 210 mg) 2 times/day                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum*\                                                                                                                                            T2DM and MS patients (*n*=50) double-blind placebo-controlled, 6 months                                                                              ↓BMI, ↓HOMA-R, ↓TC, ↓WC, ↓HbA1c, and ↓TF%                                                    ([@B94])
  (silymarin, 210 mg) 2 times/day                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum*\                                                                                                                                            T2DM and MS patients (*n*=136), placebo RCT, 52 weeks                                                                                                ↓TC, ↑HDL-C, ↓TG, ↓LDL-C, ↓HOMA-R, ↓WC, ↓TF(%), ↓VF(%), ↓UA, ↓HbA1c, ↓SBP, and ↓DBP          ([@B95])
  (silymarin, 210 mg) 2 times/day                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum*\                                                                                                                                            T2DM patients (*n* = 26), 6 months                                                                                                                   ↓HbA1c, ↓basal insulin, ↓TC, ↓LDL-C, ↓TG, ↓HOMA-R, ↓ ALT, and ↓AST                           ([@B71])
  (silymarin, 210 mg) 2 times/day                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum*\                                                                                                                                            Dyslipidemic patients (*n* =175), double blind, placebo-controlled, RCT, 6 months                                                                    ↓FPG, ↓IC, ↓HOMA, and ↓dosage of statin                                                      ([@B67])
  (silymarin, 210 mg) 2 times/day                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum*\                                                                                                                                            Euglycemic, dyslipidemic subjects (*n*=137) double-blind, RCT, placebo-controlled, 6-months                                                          ↓FPG, ↓IC, and ↓HOMA-index                                                                   ([@B68])
  (silymarin, 210 mg) 2 times/day                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Berberol ^®^ compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum*\                                                                                                                                            T2DM and hypercholesterolemic patients (*n*=45), 6-months                                                                                            ↓TC, ↓LDL-C, ↓HDL-C (only Berberol ^®^), ↓FPG, and\                                          ([@B73])
  (silymarin, 210 mg), Berberol ^®^ + statin, and Berberol ^®^ +ezetimibe; 2 times/day                                                                                                                                                                                                                                                                                             ↓HbA1c.                                                                                      

  Berberol ^®^ K compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum* (silymarin, 210 mg) and Monakopure™-K20, 50 mg; 1 time/day                                                                                Dyslipidemic patients\                                                                                                                               ↓TC, ↓LDL-C, ↓TG, and ↓CPK.                                                                  ([@B75])
                                                                                                                                                                                                                              (*n*=226), non-blind non-randomized, 6 months                                                                                                                                                                                                     

  Berberol ^®^ K compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum* (silymarin, 210 mg), and Monakopure™-K20, 50 mg; 1 time/day                                                                               Low cardiovascular risk patients (*n*=73), double-blind, placebo-controlled, RCT, 3 months                                                           ↑FPI, ↓HOMA, ↓TC, ↓TG, ↓LDL-C, and ↓hs-CRP                                                   ([@B70])

  Berberol ^®^ K compose by *B. aristata* (Berberine, BBR, 1.0 g) and *S. marianum* (silymarin, 210 mg), and Monakopure™-K20, 50 mg; 1 time/day                                                                               Diabetic and dyslipidemic patients (*n* = 59), 6 months                                                                                              ↓HbA1c, ↓TC, ↓LDL-C), and ↓TG                                                                ([@B74])

  *B. aristata* (83.3 mg), *Cyperus rotundus* (83.3 mg), *Cedrus deodara* (83.3 mg)*, Emblica officinalis* (83.3 mg), *Terminalia chebula* (83.3 mg) and *T. bellirica* (83.3 mg) 1-6 timea/day                               T2DM patients (*n*=93) Pilot RCT, 24 weeks                                                                                                           ↓PBG, ↓FBG, ↓TC, and ↓HbA1c.                                                                 ([@B25])

  *B. vulgaris* fruit\                                                                                                                                                                                                        T2DM patients (*n*=31) Double‐blind,\                                                                                                                ↓TG, ↓TC, ↓LDL-C, ↓apoB, ↓glucose, ↓insulin, and ↑TAC.                                       ([@B215])
  (aqueous extract, 3 g/day)                                                                                                                                                                                                  RCT, 3 months                                                                                                                                                                                                                                     

  *B. vulgaris* fruit\                                                                                                                                                                                                        MS patients (*n*=106) Double-blind, RCT, 6 weeks                                                                                                     ↓PAB                                                                                         ([@B178])
  (600 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  *B. vulgaris* juice\                                                                                                                                                                                                        MS patients (*n*=57) Double-blind, RCT, 8 weeks                                                                                                      ↓LDL-C, ↓TC/HDL-C ratio, ↑HDL, ↑IC, and ↑IR.                                                 ([@B79])
  (10 c.c. of processed\                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  extract/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  *B. vulgaris* fruit\                                                                                                                                                                                                        T2DM patients (*n*=30) Double-blind, RCT, 8 weeks                                                                                                    ↓SGL, ↓FG, and ↓HbA1c                                                                        ([@B177])
  (ethanolic extract 1 mg, 3 times/day)                                                                                                                                                                                                                                                                                                                                                                                                                                         

  *B. vulgaris* juice\                                                                                                                                                                                                        women diagnosed with BBD (*n* =85), 8 weeks                                                                                                          ↓IC, ↓C-peptide, ↓HOMA-IR, ↓glucose/insulin ratio, and ↑HOMA-B.                              ([@B23])
  (480 mL/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  *B. vulgaris* fruit\                                                                                                                                                                                                        (*n* = 106) Double-blind, RCT, 6 weeks                                                                                                               ↓LDL-C, ↓TC, ↑HDL-C,\                                                                        ([@B275])
  (600 mg/day)                                                                                                                                                                                                                                                                                                                                                                     ↓anti-HSPs 27, ↓anti-HSPs 60, and ↓hs-CRP                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The ↑ and ↓ signs show significant increase and significant decrease, respectively, of evaluated factors during mentioned studies. N.I., not informed.

The administration of BBR in patients with MS was found to be effective in regulating the blood glucose and blood lipid levels, improving the InsR, and reducing the level of inflammatory responses in the body ([@B38]). BBR also decreased the waist circumference, systolic blood pressure (SBP), triglycerides, and total insulin secretion along with an increase in InsS ([@B183]). BBR was suggested as a promising new hypolipidemic drug that acts through signaling pathways distinct from those of statins in the treatment of hyper mild mixed hyperlipidemia patients ([@B146]). Besides, BBR has been shown to have a good potential as a drug to control lipid metabolism alone or in combination with other drugs for hyperlipidemic hepatitis or liver cirrhosis patients ([@B269]). Moreover, BBR improved the InsS by limiting fat storage and adjusting adipokine profile in human preadipocytes and MS patients ([@B256]), and attenuated some of the metabolic and hormonal derangements in women with polycystic ovary syndrome (PCOS ([@B247]). The administration of BBR was found to be effective in the regulation of blood glucose and blood lipid in T2DM patients ([@B174]) and in improving diabetic kidney disease by reducing UACR and serum Cys C ([@B159]). On the other hand, BBR had also shown glucose-lowering activity with a mechanism different from metformin and rosiglitazone ([@B265]). In pilot study, BBR demonstrated a potent oral hypoglycemic activity with positive effects on lipid metabolism ([@B258]). Also, the benefits of BBR in lowering blood glucose, lipids, body weight, and blood pressure have been confirmed in T2DM and MS patients ([@B264]). BBR played an important role in the treatment T2DM through downregulating the higher levels of free fatty acids ([@B93]). In another study, BBR reduced the fasting plasma glucose, post-meal blood glucose, and fructosamine; however, no signification changes were found in lipid profiles, fasting insulin, HOMA-IR, and HOMA-β% in T2DM patients ([@B200]).

In addition, BBR improved the glycemic parameters comparable to metformin in T2DM patients ([@B63]). BBR significantly ameliorated T2DM *via* modulation of *Bifidobacterium* species, TNF-α, and LPS ([@B50]). BBR improved the blood lipid level in mild hyperlipidemia patients ([@B244]). Likewise, it reduced the plasma LDL-C and TG in mixed hyperlipidaemic subjects ([@B56]).

The combination of BBR and simvastatin (SIMVA) in hypercholesterolemic patients significantly improved LDL-receptor upregulation and LDL-cholesterol downregulation compared to monotherapies, and the combined effect also reduce the statins dosage ([@B147]). The administration of BBR along with red yeast and policosanol on a daily basis was found to be effective in reducing cholesterol levels and was associated with the enhancement of endothelial function and InsS ([@B4]). The administration of this supplementation in patients with familial hypercholesterolemia heterozygotes on stable treatment with LDL-C-lowering validated that the supplement reduced the LDL-C superior to that obtained by doubling the dose of statins ([@B189]).

Also, the dietary supplement Armolipid Plus™ composed of BBR, red yeast rice, policosanol, folic acid, coenzyme Q~10~, and astaxanthin showed significant reduction of cholesterolemia and positive plasma LDL-C levels in elderly (statin-intolerant) hypercholesterolemic patients ([@B168]). Moreover, it reduced LDL-C levels as well as total cholesterol/HDLc and ApoB/ApoA1 ratios, and it increased the Apo A1; tjos demonstrated the improvements in CVD risk indicators in patients with hypercholesterolemia ([@B220]) and amelioration of blood lipids and significant reduction of global CVD risk in dyslipidemic patients ([@B234]). In patients with low- to moderate-risk hypercholesterolemia, Armolipid Plus ™ in association with a hypolipidic diet significantly reduced the total cholesterol and LDL-C levels ([@B92]). In addition, Armolipid Plus ™ improved the lipid profile similar to a low dose of a standard statin and also increased the HDL-C levels and improved the leptin-to-adiponectin ratio in patients with moderate dyslipidemia and MS ([@B204]). Armolipid Plus™ alone or in combination with ezetimibe enhanced the lipid profile in statin-intolerant patients with coronary heart disease ([@B169]). BBR and Armolipid Plus™ could be a useful alternative to correct dyslipidemias and to reduce CVD risk in subjects with moderate mixed dyslipidemias ([@B57]).

Other food supplements containing BBR, including Body Lipid™, were suggested as an alternative to pharmacological treatment for patients with mild-to-moderate hypercholesterolemia ([@B61]). A new nutraceutical formulation containing BBR, monacolin K, chitosan, and coenzyme Q~10~ has proven effective in reducing non-HDL/LDL-C levels, representing an emergent therapeutic strategy in dyslipidemic patients ([@B221]). On the other hand, the combination of BBR and isoflavones was found to be effective in lowering CVD risk factors in menopausal women with moderate dyslipidaemia ([@B55]).

Treatment with BBR and rho iso-alpha acids, vitamin D3, and vitamin K1 produced a more favorable bone biomarker profile, indicative of healthy bone metabolism in postmenopausal women with MS ([@B150]). In a case--control study, BBR is more effective in decreasing the serum MGO levels and InsR through increasing the glycemic control in newly diagnosed T2DM patients ([@B171]). The intake of the natural formulation (containing BBR, orthosiphon, red yeast rice equivalent to monacolin, policosanol, folic acid, and coenzyme Q~10~) has evidenced the effective control of plasma lipids and keeps borderline high blood pressure within normal values compared with diet alone ([@B167]).

Stem powder of *B. aristata* was found to be effective in improving glycemic control and lipid profiles with no major adverse effects on T2DM patients ([@B213]). The effect of *B. vulgaris* extract on T2DM and MS patients has been widely studied in humans. The intake of 3 g/d of *B. vulgaris* fruits aqueous extract for 3 months may have beneficial effects on lipoproteins, apoproteins, glycemic control, and TAC in T2DM patients ([@B215]). *B. vulgaris* juice reduced oxidative burden in patients with MS ([@B178]). Other study showed the beneficial effects of processed *B. vulgaris* on certain atherosclerosis risk factors in T2DM patients ([@B79]). *B. vulgaris* fruit extract showed beneficial metabolic effects in T2DM patients, improving the glucose catabolism *via* the glycolysis pathway, stimulating the insulin secretion or improving the insulin function, and later decreasing the glucose uptake ([@B177]). Another study demonstrated that the *B. vulgaris* juice evoked regulatory roles on HOMA-IR and improved HOMA-B with the metabolic controlling insulin-related indices in benign breast disease ([@B23]). Also, *B. vulgaris* supplementation in patients with MS significantly diminished anti-HSPs 27 and 60 and hs-CRP levels and improved lipid profiles ([@B275]). It is reported that the Hsp60 protein is able to induce the production of anti-Hsp60 antibodies, which leads to the destruction of β-islet cells. In the same way, Hsp60 acts as a proinflammatory signaling molecule, which plays a role in the non-resolved vascular inflammation, and this is recognized as one of the characteristic of T2DM ([@B117]). Others natural formulations containing *Berberis* have also been tested in humans. A clinical trial demonstrated that daily intake of polyherbal capsule composed by *B. aristata* and *Cyperus rotundus*, *Cedrus deodara*, *Emblica officinalis*, *Terminalia chebula*, and *T. bellirica* decreased the glucose level, enhanced lipid homeostasis, and maintained other serum biochemical levels to the normal in patients with T2DM ([@B25]).

The nutraceutical product Berberol^®^, containing a *B. aristata* extract (titrated in 85% BBR) plus a *Silybum marianum* extract (titrated in 60% silymarin), has been evaluated for its antidiabetic potential in humans. Berberol^®^ was demonstrated to be more effective than BBR alone (administered at the same dose), reducing HbA1c in T2DM patients ([@B72]). The incorporation of Berberol^®^ into insulin therapy in patients with T1DM has the effect of a diminution of the insulin dose necessary for adequate glycemic control ([@B69]). In dyslipidemic patients, Berberol^®^ has proven to be safe and effective in improving lipid profile, InsR, and adipocytokines levels ([@B66]). Berberol^®^ also improved the cholesterol-lowering properties of statins and showed the positive effects on liver enzymes and glycemic control in patients with T2DM ([@B94]). In addition, Berberol^®^ significantly lowered abdominal adiposity and decreased the circulating uric acid level in overweight/obese patients with T2DM ([@B95]). Berberol^®^ was suggested as a good candidate for an adjunctive treatment option in diabetes, especially in patients with suboptimal glycemic control ([@B71]). Berberol^®^ administered as a single or add-on therapy in statin-intolerant subjects is an effective treatment to improve the lipidic and glycemic profiles in T2DM and hypercholesterolemia patients ([@B73]). The combination of Berberol^®^ and a reduced dosage of statin is found effective for the treatment of hyperlipidemia in patients intolerant to statins at high dosage ([@B67]) and in dyslipidemic euglycemic patients ([@B68])

Berberol K^®^, was found to be a potentially good alternative in primary intervention in low cardiovascular-risk subjects with dyslipidemia, as an add-on therapy in mildly statin-intolerant patients, and as an alternative for dyslipidemic patients with a negative perception of statins ([@B74]). Berberol K^®^ reduced lipid profile effectively and improved the inflammatory parameters under a safe dose ([@B70]). It was also found to be effective in diabetic subjects with dyslipidemia statin intolerant or with diarrhea caused by IBS or metformin ([@B75]).

Few studies have also reported the effectiveness of BBR in non-alcoholic fatty liver disease (NAFLD). NAFLD is a result of abnormal fat accumulation in the liver due to the reasons other than alcohol, and it is considered to be a hepatic manifestation of MS. NAFLD results in the overproduction of sugars and triglycerides and plays a central role in the development of InsR and various other glucose- and lipid metabolism-related diseases ([@B259]). Recently, [@B255] conducted a randomized, parallel controlled, open-label clinical trial in 188 NAFLD patients. Patients received lifestyle intervention (LSI) or LSI and 15 mg of pioglitazone qd or LSI and of BBR for 16 weeks. Parameters, including hepatic fat content, serum glucose level, serum lipid profiles, liver enzymes, and serum and urine BBR concentrations, were measured before and after treatment. LSI and BBR showed a reduction in hepatic fat content as compared to LSI and were better than pioglitazone in reducing body weight and resulted in better lipid profiles ([@B255]). Furthermore, a mechanism-based study revealed that BBR reduced hepatic TG accumulation and decreased the expressions of hepatic stearyl-coenzyme A desaturase 1 (SCD1) and other TG synthesis-related genes ([@B274]). Berberine administration was also reported to recruit and activate BAT in both humans and mice ([@B250]).

Conclusion {#s9}
==========

Although there are many effective therapeutic drugs for the treatment of metabolic diseases, the current treatment did not control the rapid increasing trend in diabetes mortality and morbidity. Various therapeutic agents from both natural and synthetic sources are being investigated in patients with clinical signs of diabetic and other metabolic diseases. Formulations prepared from the various plant parts of *Berberis* species were found to be used traditionally in the treatment of diabetes and other metabolic diseases and related complications. A review of the scientific literature revealed that the extracts, isolated alkaloids from *Berberis* species including BBR and their derivatives, have shown promising effects in the studies related to diabetes and other metabolic diseases. The relatively low cost of BBR or supplements or extracts containing BBR, compared to other synthetic medications, will be of an advantage to the patients living in developing countries with poor socioeconomic circumstances. However, currently available scientific evidence is still not fully sufficient to prove their efficacy clinically. Further randomized double-blind clinical trials with a large number of patients and standardized clinical assessments are required to prove the effectiveness of the *Berberis* extracts and isolated compounds on metabolic diseases alone or in combinations. Novel pharmacological assessment techniques and analytical techniques will further provide additional opportunities for these agents. Moreover, the development of novel formulations of berberine could be an effective strategy for increasing its effectiveness against diabetes and other metabolic diseases.
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